Literature DB >> 11962108

Prenatal HIV screening in a tertiary care centre.

A Gruslin1, A Salvador, M Dekker, D Menard-de Varennes, E Eason.   

Abstract

OBJECTIVE: Strategies are available to reduce maternal-fetal transmission of HIV and depend on adequate prenatal screening. At present, a significant proportion of Canadian pregnant women remain unscreened. We reviewed our screening practices before and after the implementation of a departmental policy on universal counselling for HIV screening and the distribution of a patient educational brochure developed at our centre (interventions).
METHODS: Charts of all new antenatal patients seen during February-April in 1996 (n = 186) and 1998 (n = 212) were reviewed. Maternal demographics and evidence of HIV counselling and screening were collected and analyzed.
RESULTS: Following our interventions, HIV counselling and screening rates increased from 13% to 72%. Patient acceptance of testing was high. The majority of missed opportunities for HIV testing were patients transferred urgently from other institutions.
CONCLUSION: HIV counselling and screening can be improved by implementation of local strategies. We have demonstrated the feasibility of this approach in a tertiary care unit.

Entities:  

Mesh:

Year:  2001        PMID: 11962108

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  3 in total

1.  Aiming for zero: preventing mother-to-child transmission of HIV.

Authors:  Kathleen Steel O'Connor; Susan E MacDonald
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices.

Authors:  Mark Downing; Laura Youden; Beth A Halperin; Heather Scott; Bruce Smith; Scott A Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

3.  High uptake of HIV testing in pregnant women in Ontario, Canada.

Authors:  Robert S Remis; Maraki Fikre Merid; Robert W H Palmer; Elaine Whittingham; Susan M King; Natasha S Danson; Lee Vernich; Carol Swantee; Carol Major
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.